IMD incidence for persons diagnosed with HIV was calculated using the national cohort of persons diagnosed and living with HIV [16]
IMD incidence for persons diagnosed with HIV was calculated using the national cohort of persons diagnosed and living with HIV [16]. 100, 000 among HIV-negative individuals, with a relative risk of 4. 5 (95 % CI, SIX3 2 . 77. 5). All but one case occurred in adults aged 1664 years, who had a 22. 7-fold (95 % CI, 12. 441. 6; P <0. 001) increased risk compared with the HIV-negative adults. IMD risk by capsular group varied with age. HIV-positive children and adolescents had a higher risk of meningococcal group B disease, while adults were at increased risk of groups C, W and Y disease. Most HIV-positive individuals had CP 945598 HCl (Otenabant HCl) been born in Africa, had acquired HIV through heterosexual contact, and were known to be HIV-positive and receiving antiretroviral treatment at IMD diagnosis. The most common clinical presentation was septicemia and, although intensive care admission was common, none died of IMD. == Conclusions == HIV-positive children and adults are at significantly increased risk of IMD, providing an evidence base for policy makers to consider HIV as a risk factor for meningococcal vaccination. Keywords: HIV, Invasive meningococcal disease, Serogroup, Vaccination, Relative risk == Background == Neisseria meningitidis, commonly known as the meningococcus, is a major global cause of meningitis and septicaemia, and is associated with significant morbidity and mortality across all age CP 945598 HCl (Otenabant HCl) groups [1]. Twelve distinct polysaccharide capsules have been described, including five that are responsible for almost all cases of invasive meningococcal disease (IMD) globally: A, B, C, W and Y [1]. In the United Kingdom, as in most of Europe, meningococcal groups B (MenB) and C (MenC) were previously responsible for nearly all IMD cases [2]. Invasive MenC disease, however , is now uncommon since routine vaccination against MenC was introduced in 1999, with most cases now occurring in unvaccinated adults who acquire the infection abroad [2]. MenB, therefore , has been responsible for 8090 % of all IMD cases, with the highest incidence in infants ( <1 year-olds) and toddlers (14 year-olds), and with a small secondary peak in adolescents and young adults [3]. Meningococcal groups W (MenW) and Y (MenY) are uncommon and mainly cause disease in older adults, although the UK is currently experiencing a national outbreak of MenW disease across all age groups, following endemic expansion of a single hypervirulent strain belonging to the ST-11 clonal complex CP 945598 HCl (Otenabant HCl) [4]. Unlike older adults (65 year-olds), the vast majority of children and young adults who develop IMD are previously healthy. The only significant risk factors for IMD are complement deficiency and asplenia/splenic dysfunction [5]. These risk groups are currently advised to receive the meningococcal quadrivalent conjugate vaccine (MenACWY) and the recently licensed multi-component protein-based MenB vaccine (Bexsero, Novartis, Basel, Switzerland). They may also be on penicillin prophylaxis, which should provide additional protection against IMD [5]. Both these vaccines will be included in the UK national infant and adolescent immunisation programmes, respectively, later this season [5]. Unlike additional encapsulated bacteria, such asStreptococcus pneumoniaeandHaemophilus influenzaetype b (Hib), immunosuppression (primary or acquired) has not been deemed a significant risk factor designed for IMD [5]. Although the British HIV Association (BHIVA) testing recommendations recommend the quadrivalent vaccine containing A, C, Watts and Con, for holidaymakers considered to be at risk or in touch with these capsular groups [6], HIV-positive individuals are not recommended to receive any additional vaccinations against IMD apart from the scheduled schedule MenC dosages, irrespective of their particular degree of immunosuppression or HIV treatment status [713]. The objective of this study was to assess the risk of IMD simply by age and capsular group in individuals diagnosed with HIV in England. Evaluation was performed using nationwide data designed for the three latest years, while using aim of producing an facts base designed for recommending meningococcal vaccination with this vulnerable group. == Methods == == Meningococcal monitoring == Public well-being CP 945598 HCl (Otenabant HCl) England (PHE) conducts improved national monitoring of IMD and records more than ninety five % of laboratory-confirmed instances in England [3]. Included in the enhanced monitoring, the PHE Meningococcal Guide Unit (MRU) provides a nationwide service designed for species verification and grouping/typing of invasiveN. meningitidisisolates, that are not regularly performed simply by National Overall health Service (NHS) hospital laboratories. The MRU also offers free of charge PCR tests for meningococcal DNA in clinical specimens (e. g. blood, cerebrospinal fluid, joint fluid, pleural fluid), that are routinely posted by NHS hospital laboratories throughout Britain [3]. Species verification and capsular group willpower were performed as defined previously [14]. Seeing that 1 January 2011, most laboratory-confirmed instances are followed-up by asking for the sufferers general practitioner (GP) to develop a short set of questions requesting.